Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevac...

ver descrição completa

Detalhes bibliográficos
Autores: Jantus-Lewintre, E, Sureda, BM, Larriba, JLG, Rodriguez-Abreu, D, Juan, O, Blasco, A, Domine, M, Pulla, MP, Garde, J, Alvarez, R, Maestu, I, de Carrion, RP, Artal, A, Rolfo, C, de Castro, J, Guillot, M, Oramas, J, de las Penas, R, Ferrera, L, Martinez, N, Serra, O, Rosell, R, Camps, C, Grp Espanol Canc Pulmon GECP
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Centro de Investigación Principe Felipe (CIPF)
Repositorio:r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
OAI Identifier:oai:cipf.fundanetsuite.com:p3805
Acesso em linha:https://cipf.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3805
Access Level:acceso abierto
Palavra-chave:liquid biopsy
biomarkers
NSCLC
angiogenesis
VEGF
id ES_871294dfa497faf41f56ca2aed2dae80
oai_identifier_str oai:cipf.fundanetsuite.com:p3805
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET StudyJantus-Lewintre, ESureda, BMLarriba, JLGRodriguez-Abreu, DJuan, OBlasco, ADomine, MPulla, MPGarde, JAlvarez, RMaestu, Ide Carrion, RPArtal, ARolfo, Cde Castro, JGuillot, MOramas, Jde las Penas, RFerrera, LMartinez, NSerra, ORosell, RCamps, CGrp Espanol Canc Pulmon GECPliquid biopsybiomarkersNSCLCangiogenesisVEGFFinding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy.FRONTIERS MEDIA SA2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://cipf.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3805Frontiers in OncologyISSN: 2234943Xreponame:r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)instname:Centro de Investigación Principe Felipe (CIPF)Inglésinfo:eu-repo/semantics/openAccessoai:cipf.fundanetsuite.com:p38052026-06-17T11:19:47Z
dc.title.none.fl_str_mv Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
title Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
spellingShingle Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
Jantus-Lewintre, E
liquid biopsy
biomarkers
NSCLC
angiogenesis
VEGF
title_short Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
title_full Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
title_fullStr Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
title_full_unstemmed Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
title_sort Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
dc.creator.none.fl_str_mv Jantus-Lewintre, E
Sureda, BM
Larriba, JLG
Rodriguez-Abreu, D
Juan, O
Blasco, A
Domine, M
Pulla, MP
Garde, J
Alvarez, R
Maestu, I
de Carrion, RP
Artal, A
Rolfo, C
de Castro, J
Guillot, M
Oramas, J
de las Penas, R
Ferrera, L
Martinez, N
Serra, O
Rosell, R
Camps, C
Grp Espanol Canc Pulmon GECP
author Jantus-Lewintre, E
author_facet Jantus-Lewintre, E
Sureda, BM
Larriba, JLG
Rodriguez-Abreu, D
Juan, O
Blasco, A
Domine, M
Pulla, MP
Garde, J
Alvarez, R
Maestu, I
de Carrion, RP
Artal, A
Rolfo, C
de Castro, J
Guillot, M
Oramas, J
de las Penas, R
Ferrera, L
Martinez, N
Serra, O
Rosell, R
Camps, C
Grp Espanol Canc Pulmon GECP
author_role author
author2 Sureda, BM
Larriba, JLG
Rodriguez-Abreu, D
Juan, O
Blasco, A
Domine, M
Pulla, MP
Garde, J
Alvarez, R
Maestu, I
de Carrion, RP
Artal, A
Rolfo, C
de Castro, J
Guillot, M
Oramas, J
de las Penas, R
Ferrera, L
Martinez, N
Serra, O
Rosell, R
Camps, C
Grp Espanol Canc Pulmon GECP
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv liquid biopsy
biomarkers
NSCLC
angiogenesis
VEGF
topic liquid biopsy
biomarkers
NSCLC
angiogenesis
VEGF
description Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://cipf.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3805
url https://cipf.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3805
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Oncology
ISSN: 2234943X
reponame:r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
instname:Centro de Investigación Principe Felipe (CIPF)
instname_str Centro de Investigación Principe Felipe (CIPF)
reponame_str r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
collection r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412419972890624
score 15.812429

Registos relacionados